FDA Approves First Drug to Treat Hallucinations, Delusions in Patients with Parkinson Disease

May 27, 2016 | Strategic Insights for Ambulatory Care


​The U.S. Food and Drug Administration (FDA) recently approved Nuplazid (pimavanserin), the first drug approved to treat hallucinations and delusions associated with psychosis occurring in some patients with Parkinson disease, states an April 29, 2016 FDA press release. As many as 50% of patients with Parkinson disease may exhibit these symptoms at some point during the course of the illness, states FDA.

Access Full Content

Contact us today at 610.825.6000.